Given the costs of CAR T-Cell therapy, it is not sustainable to cover all patients who require access to this.
Drugs can cost up to $ 500,000. On top of this is the actual patient treatment and follow-up care. All in all, each patient can expect to run up to $ 1 million in expenses.
It is recommended that patients whose only option for a treatment is CAR T-Cell to be covered.
Many providers do not cover stem cell therapy treatments. This is because stem cells were being widely used without sufficient proof of effectivity.
However,here is evidence that the therapy is effective for those with Acute Lymphoblastic Leukemia and relapsed diffuse Large B-cell Lymphoma.
Clinicians and payers should continue collaborating to pick the most suitable patients for these therapies, if these are included in the coverage.